» Articles » PMID: 29129825

Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction

Overview
Journal Turk J Haematol
Specialty Hematology
Date 2017 Nov 14
PMID 29129825
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Nucleophosmin-1 (NPM1) mutations have prognostic importance in acute myeloid leukemia (AML) patients with intermediate-risk karyotype at diagnosis. Approximately 30% of newly diagnosed cytogenetically normal AML (CN-AML) patients harbor the NPM1 mutation in India. In this study we compared the efficiency of three molecular techniques in detecting NPM1 mutation in peripheral blood and bone marrow samples.

Materials And Methods: In a single-center cohort we analyzed 165 CN-AML bone marrow/peripheral blood samples for NPM1 mutation analysis. About 30% of the CN-AML samples revealed NPM1 mutations. For the detection, three methods were compared: Sanger sequencing, pyrosequencing, and real-time polymerase chain reaction (PCR).

Results: NPM1 exon 12 mutations were observed in 52 (31.51%) of all CN-AML cases. The sensitivity of Sanger sequencing, pyrosequencing, and real-time PCR was 80%, 90%, and 95%, whereas specificity was 95%, 100%, and 100%, respectively. The minimum limit of mutation detection was 20%-30% for Sanger sequencing, 1%-5% for pyrosequencing, and 0.1%-1% for real-time PCR.

Conclusion: The sequencing method, which is the reference method, has the lowest sensitivity and is sometimes difficult to interpret. Real-time PCR is a highly sensitive method for mutation detection but is limited for specific mutation types. In our study, pyrosequencing emerged as the most suitable technique for the detection of NPM1 mutations on the basis of its easy interpretation and less time-consuming processes than Sanger sequencing.

Citing Articles

Detecting Azole-Antifungal Resistance in by Pyrosequencing.

van der Torre M, Novak-Frazer L, Rautemaa-Richardson R J Fungi (Basel). 2020; 6(1).

PMID: 31936898 PMC: 7151159. DOI: 10.3390/jof6010012.


Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.

Ohtsuka T, Tomosugi T, Kimura R, Nakamura S, Miyasaka Y, Nakata K Surg Today. 2019; 49(11):887-893.

PMID: 30879148 DOI: 10.1007/s00595-019-01797-7.


Ultra-deep amplicon sequencing indicates absence of low-grade mosaicism with normal cells in patients with type-1 NF1 deletions.

Summerer A, Schafer E, Mautner V, Messiaen L, Cooper D, Kehrer-Sawatzki H Hum Genet. 2018; 138(1):73-81.

PMID: 30478644 DOI: 10.1007/s00439-018-1961-5.

References
1.
Liu Y, He P, Liu F, Shi L, Zhu H, Zhao J . Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis. Mol Clin Oncol. 2014; 2(2):275-281. PMC: 3917771. DOI: 10.3892/mco.2013.222. View

2.
Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C . Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005; 7(3):413-21. PMC: 1867544. DOI: 10.1016/S1525-1578(10)60571-5. View

3.
Jancik S, Drabek J, Berkovcova J, Xu Y, Stankova M, Klein J . A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas. J Exp Clin Cancer Res. 2012; 31:79. PMC: 3542008. DOI: 10.1186/1756-9966-31-79. View

4.
Gale R, Green C, Allen C, Mead A, Burnett A, Hills R . The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2007; 111(5):2776-84. DOI: 10.1182/blood-2007-08-109090. View

5.
Falini B, Martelli M, Pileri S, Mecucci C . Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help. Haematologica. 2010; 95(4):529-34. PMC: 2857180. DOI: 10.3324/haematol.2009.017822. View